230 related articles for article (PubMed ID: 15896237)
1. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
[TBL] [Abstract][Full Text] [Related]
2. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
Feng Y; Green B; Duffull SB; Kane-Gill SL; Bobek MB; Bies RR
Br J Clin Pharmacol; 2006 Aug; 62(2):165-76. PubMed ID: 16842391
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
4. Dosage of enoxaparin among obese and renal impairment patients.
Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
6. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin.
Chow SL; Zammit K; West K; Dannenhoffer M; Lopez-Candales A
J Clin Pharmacol; 2003 Jun; 43(6):586-90. PubMed ID: 12817521
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
8. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
Hulot JS; Montalescot G; Lechat P; Collet JP; Ankri A; Urien S
Clin Pharmacol Ther; 2005 Jun; 77(6):542-52. PubMed ID: 15961985
[TBL] [Abstract][Full Text] [Related]
9. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
Ma JM; Jackevicius CA; Yeo E
Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
[TBL] [Abstract][Full Text] [Related]
10. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
[TBL] [Abstract][Full Text] [Related]
12. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
Lachish T; Rudensky B; Slotki I; Zevin S
Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889
[TBL] [Abstract][Full Text] [Related]
13. Experience with intravenous enoxaparin in critically ill infants and children.
Crary SE; Van Orden H; Journeycake JM
Pediatr Crit Care Med; 2008 Nov; 9(6):647-9. PubMed ID: 18838932
[TBL] [Abstract][Full Text] [Related]
14. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
[TBL] [Abstract][Full Text] [Related]
17. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
19. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA
J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608
[TBL] [Abstract][Full Text] [Related]
20. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
